drugset
drugset / Trial / NCT05012761

The Pharmacokinetics (PK), Safety, Tolerability of SR419 in Healthy Volunteers

NCT05012761 ↗

Phase 1 Completed 40 enrolled Shanghai SIMR Biotechnology Co., Ltd.
RandomizedSequentialTriple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled phase I PK bridging study to evaluate the PK, safety and tolerability of SR419 in healthy subjects.

Timeline

Start
2021-08-24
Primary completion
2021-12-27
Completion
2022-05-27

Drugs

EvaluationDrugModalityDoseRoute
Subject SR419 Unknown — Oral

Indications

No indication recorded.